This might be the best time to buy in. The amount of money invested by the company to commercialize its vaccine has yet to materialize but in near future the potential earnings brought by the approved vaccines can make it a milionaire-maker stock.
Story of what happen:
- Initially, $Histogenics(OCGN)$ wanted to apply for Emergency Use Authorization (EUA) which will facilitate the availability and use of medical countermeasures,including vaccines, during public health emergencies, such as the current COVID-19 pandemic. With the EUA approval, $Histogenics(OCGN)$ is able to launch is vaccine in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives.
- However, now they decided to pursue the full US approval (FDA/BLA) which is the Biologics license application which might just cause slightly more delay. Even the popular vaccines such as $Moderna, Inc.(MRNA)$ , $Pfizer(PFE)$ and$Johnson & Johnson(JNJ)$have yet to obtain FDA approval, only the emergency use approval. Hence, the slight delay is really nothing much to be worried about.
- In addtion, the intention of $Histogenics(OCGN)$is very clear cut and justified by the USD 15 million upfront investment to extend the vaccine rights and another USD 10 million from the launch of Covaxin in Canada and North America. With such investment being made, that clearly shows the confidence in its vaccines and also the desire to commercialize it.
Also, Ocugen reports strong phase 3 results for Corona virus during April and I
strongly believed that it might not be long that $Histogenics(OCGN)$ might get full approval.
精彩评论